Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Thanks to this tiny piece of tech, people with profound vision loss can now read, do cross word puzzles, and navigate public ...

Microarray technology encompasses a few relatively well-established methods and numerous applications that are in various stages of development. Apart from their use as a tool for diagnostic testing ...

Long before a liver tumor appears, a high-fat diet can push liver cells into a risky survival mode. That is the central ...

Vaxxas Pty Ltd today announced the appointment of global biopharmaceutical executive Mr David Peacock as Chief Executive ...

Vaxxas has appointed former Merck Global Vaccines president David Peacock as chief executive officer (CEO), marking a step in ...

Brisbane-based Vaxxas has appointed David Peacock to lead the push to bring its vaccine patch technology to market.

Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through ...

Completion of the Human Genome Project has been rapidly followed by the emergence of high-throughput technologies that combine automation, miniaturization, and many other strategies and tools to ...

Nandita Vijayasimha, Bengaluru Friday, January 2, 2026, 08:00 Hrs [IST] ...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

Well, a global provider of genomic library and multiplexing workflow solutions, today announced the launch of AgriPreptm Library Prep Kit, the newest addition to its next-generation TnXtm transposase ...